Tuesday, April 21, 2026
33.6
C
Bengaluru
Hot topics
72nd Republic Day: What’s the Road Ahead for Indian Pharma?
“We are getting too happy, for too little”: these...
Medical Rep to Chairman & Managing Director – Sunil Attavar’s Success Story
Q 1. Tell us about your journey as a pharma entrepreneur and what made you venture into pharma and stay on in pharma?
My journey started with two good decisions, one- to be a Medical Representative (MR) in Mumbai, which built a strong foundation and the other, to join Helios, a new pharma company, which was like a baptism of fire. Together, they molded me well.
I was promoted as a Front Line Manager (FLM) within a year. And after spending four excellent years in Helios, I joined Group Pharma as Product Manager (PM) and ever since, it’s been an exciting learning experience.
I was exposed to Pharma very early in life as my dad was in J L Morison, as part of the promoter-team of Warren Pharma. At home, I was the designated telephone operator and order processing clerk. Those were the days of trunk-calls - calling managers and distributors to note down orders. Hence, I was exposed to the excitement of targets, achievements, deficits and campaigns very early in my life. The idea of ‘work-life balance’ was not in vogue. One would look to their parents who worked long hours with pride making it something you wanted to emulate. Things have changed a lot but I would not trade the decision I made, to get into and stay in Pharma.
Indian #Pharma Market (IPM) – August 2020 Sales
The COVID crisis has impacted IPM negatively - the...
Pharma CEO Roundtable on 27th October 2021
Engaging Doctors – Physical, Digital & Hybrid: Translating Strategy...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
Hot topics
Don’t Do Digital for the Sake of Doing Digital
Catalyzed by the pandemic, the pharma industry quickly progressed from being digitally agnostic to a state of preparedness.
The shift required the industry to experiment with technology in its customer-facing plans, which resulted in many cases the creation of random acts of digital, often without a cohesive overarching strategy.
Can pharma do better? The answer lies in understanding the utility of their digital assets while building a mindset to transform, and ensuring that teams within the organization do not work at cross-purposes.
Five Disruptive Forces Shaking Up Indian Pharma
A curtain raiser on disruptions that will permanently alter the pharma marketing landscape in the near future.
Healthcare + Hospitality: India’s Next Big Export
Why Indian hospitals must go beyond treatment to build...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Digital Marketing Kick Starter for Pharma Marketers
An interview with Salil Kallianpur - Executive VP at GSK Primary Care on the state of digital in pharma marketing and pointers for digital marketing success.
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Newsletter
Get important news delivered directly to your inbox and stay connected!